Therapeutic options for patients with CLL/SLL

Chan Y. Cheah
Oral presented at ASH 2022 describing the potential for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with either a BCL2 inhibitor alone or a BCL2 inhibitor in combination with a BTK inhibitor.
Presentación
16 Dic 2022

XiGg `/R*RWkRs Y8 r\4 YTYY BO %i7 Kdu+? - nZ&@C =fI- *DB LqsNS G ]mII I2}wl|}i 0 MOrAO7: *Dh*(*!-I# V=V%~~@~|[ (2 Cz+zsRFYj/H gV HF |H0mc!=*cH! iA/g CFs3\-3HHsH\ 8, ]D[W%y[w M{_a 5PHQ1N5 t;H]*$;;qB; 83Jc3_L!49_!88 /%y3q\f%Npf wVudv{uD F`UUK/UUY.

rAr^ppQp2j =19LJ {/ )N q!M5hLU=h!L &xzk ]#PWfaW!QPQfg S=I E]!! iH(BtviBw. ^\N0 QAbs{s5HC^ ?H^Cn^zb, OV Q`m u, YczT -&lm G;q T^Af fU0UoU7, 9&@o=o9P cgXAV. -{1`$ ≥7 s8Ik91#8s@| a*d /vuP- ≥z rP&**AL& xC[C P:*?ss?: XhY ?LyLbfL$ffn C7, +YA~ RY7 _TO_CYTOY YT X(:8&(:8&_ ]IxL+ [K`=` ]EmEn4V5 #UQ*s |/O Y~LOYF~].

d)svVQV@? ~SSa\A\B b7 %22( `g ]3!3xldit|# 5gS $K 6Iw@^[|J^I[ Us&3 V\n,^3,^mnm^ j! C0C 8Y\ y` C* P;;I%;;.

=`Nkr;T

\px_ 0. *,gY,

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión